A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

NCT05071300 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

151

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Interventions

DRUG: Eplontersen

Sponsor

Ionis Pharmaceuticals, Inc.